PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects

Tyler J. Fraum, Daniel R. Ludwig, Thomas A. Hope, Kathryn J. Fowler

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.

Original languageEnglish
Pages (from-to)691-714
Number of pages24
JournalGastroenterology Clinics of North America
Issue number3
StatePublished - Sep 2018


  • Colorectal cancer
  • Hepatocellular carcinoma
  • Neuroendocrine tumor
  • Pancreatic cancer


Dive into the research topics of 'PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects'. Together they form a unique fingerprint.

Cite this